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Abstract
Background: Despite many decades of declining mortality rates in the Western world, cardiovascular disease remains the
leading cause of death worldwide. In this research we evaluate the optimal mix of lifestyle, pharmaceutical and population-
wide interventions for primary prevention of cardiovascular disease.
Methods and Findings: In a discrete time Markov model we simulate the ischaemic heart disease and stroke outcomes and
cost impacts of intervention over the lifetime of all Australian men and women, aged 35 to 84 years, who have never
experienced a heart disease or stroke event. Best value for money is achieved by mandating moderate limits on salt in the
manufacture of bread, margarine and cereal. A combination of diuretic, calcium channel blocker, ACE inhibitor and low-cost
statin, for everyone with at least 5% five-year risk of cardiovascular disease, is also cost-effective, but lifestyle interventions
aiming to change risky dietary and exercise behaviours are extremely poor value for money and have little population
health benefit.
Conclusions: There is huge potential for improving efficiency in cardiovascular disease prevention in Australia. A tougher
approach from Government to mandating limits on salt in processed foods and reducing excessive statin prices, and a shift
away from lifestyle counselling to more efficient absolute risk-based prescription of preventive drugs, could cut health care
costs while improving population health.
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Introduction
Despite many decades of declining mortality rates in the
Western world [1,2], cardiovascular disease (CVD) remains the
leading cause of death worldwide [3]. In countries such as the
United States (US), United Kingdom (UK) and Australia, the
majority of cardiovascular burden could be prevented by better
addressing key risks, such as blood pressure and cholesterol
levels [4–6].
Many countries have already developed guidelines and imple-
mented interventions for primary prevention of CVD. Most
guidelines recommend lifestyle behaviour-change approaches as a
first line strategy, with blood pressure-lowering and/or cholesterol
drugs for those at highest risk [7]. In England, for example, the
new Vascular Check program aims to screen all adults aged
between 40 and 74 years, targeting those at risk with a
combination of lifestyle interventions, blood pressure-lowering
drugs and statin drugs, where indicated [8]. Some countries have
also implemented community- or population-wide interventions;
many community-level heart health programs were run between
the 1970s and 1990s [9], and countries, such as Finland and the
UK, have also established long-term programs to reduce
population dietary salt levels [10].
With rising health care costs, it is vital that countries combine
intervention strategies that will achieve maximum improvement in
cardiovascular health at lowest cost to the health sector. Cost-
effectiveness analyses for the WHO-CHOICE program in 2000,
showed that a combination of beta-blocker, diuretic, statin and
aspirin could be cost-effective, if provided to everyone with at least
a 5% probability of a cardiovascular event in the next ten years, in
regions with low child and adult mortality (e.g. UK, US and
Australia) [11]. Newer evidence on drug efficacy [12,13], including
alternative blood pressure-lowering drugs such as calcium channel
blockers and ACE inhibitors, the changing price of statins [14–16],
and increasing doubts about the use of aspirin in primary
prevention [17,18], however, may mean that this is no longer
the optimal strategy for intervention. More recently, England’s
Department of Health has estimated that the new Vascular Check
program combining lifestyle intervention with drugs (statins, ACE-
inhibitors and calcium channel blockers) for those at highest risk
will be highly cost-effective (£3000/QALY ; A$6,700/QALY
[19]) [8,20]. Although this has not been compared with the cost-
effectiveness of population-wide strategies, analyses from WHO-
CHOICE, Argentina, Vietnam, the UK, US and Australia, have
found that population-wide strategies, particularly salt reduction
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programs are likely to be even more cost-effective [11,21,22] and
potentially even cost-saving [23–25].
Australia is currently re-visiting its guidelines for primary
prevention of cardiovascular disease. In this research we evaluate
the optimal mix of lifestyle, pharmaceutical and population-wide
interventions from an Australian health sector perspective. We also
evaluate the current practice of blood pressure and cholesterol
intervention in Australia, and examine this against the optimal
mix, to quantify the potential for improving population health and
reducing health sector expenditure.
Methods
Ethics Statement
The study was approved by the Behavioural & Social Sciences
Ethical Review Committee of the University of Queensland in
accordance with the National Health and Medical Research
Council guidelines (Clearance no. 2004000796). The study was
based on analysis of publically available data. It did not involve
human participants or require informed consent.
We evaluate cost-effectiveness of interventions to prevent CVD
in the 2008 Australian population of 35 to 84 year olds who have
not previously experienced a CVD event (defined as angina,
myocardial infarction or stroke). We include two interventions
targeting the whole population, a community heart health
program and mandatory reduction of salt in the manufacture of
breads, margarines and cereals; six interventions targeting those at
increased risk of disease with pharmacological agents, diuretics,
ACE inhibitors, calcium channel blockers, beta-blockers, statins
and aspirin; and three interventions targeting those at increased
risk of disease with interventions to change behaviour, dietary
advice from a doctor or dietitian, referral to a more intensive
lifestyle program with specialised counselling, and advice from a
doctor to switch to phytosterol-enriched margarine. We also
model the current practice coverage of these interventions for
primary prevention of CVD in Australia. Key components of
current practice include voluntary (rather than mandatory)
reduction of salt in breads, margarines and cereals; dietary advice
from a general practitioner (GP); and blood pressure- and
cholesterol-lowering drug therapies.
Intervention Uptake and Adherence
Two of the interventions, the community heart health program
and reduction of salt in processed foods, are delivered to the whole
population. We assume the average population effect of these
interventions is sustained with ongoing delivery of the interven-
tions.
All other interventions are delivered in primary care. We
determine the annual number of 35 to 84 year olds visiting a GP
from an Australian GP sample registration system [26] and
determine GP participation in CVD risk assessment from GP
involvement in Australia’s Practice Incentives Program [27].
Eligibility for preventive therapy is based on an individual’s risk
of a CVD event over the next five years [28], divided into three
levels of risk: $15%, 10–14% and 5–9%.
We determine the probability of an event using the Framing-
ham risk prediction equation [29]. The equation is calibrated for
the Australian population using probabilities of a first-ever
ischaemic heart disease or stroke event (derived from Australian
hospital and mortality databases [30,31], the Perth MONICA
study [32] and the NEMESIS [33] study) and individual-level data
from Australia’s AusDiab 1999–2000 data set [34]. The AusDiab
data used in the Framingham equation include age, sex, smoking
status, total cholesterol level, high density lipoprotein cholesterol
level and diabetes status, for everyone who has not had an
ischaemic heart disease or stroke event. Rather than altering the
parameters of the Framingham risk prediction equation, we scale
Table 1. Intervention costs and effects.
Intervention Annual cost per person* Measure of effect Effect size Sources**
Thiazide diuretic $71 RR IHD RR stroke 0.86 (0.06) 0.62 (0.05) [13,37,38]
Beta-blocker $106 RR IHD RR stroke 0.89 (0.06) 0.83 (0.07) [13,37,38]
Calcium channel blocker $218 RR IHD RR stroke 0.85 (0.04) 0.66 (0.04) [13,37,38]
ACE inhibitor $212 RR IHD RR stroke 0.83 (0.03) 0.78 (0.07) [13,37,38]
Aspirin $40 RR IHD RR stroke (isch.) RR stroke
(haem.) RR GI bleed
0.82 (0.04) 0.86 (0.07)
1.32 (0.19) 1.54 (0.13)
[37,71–73]
Statin Aust.: $687 NZ: $19 RR IHD RR stroke 0.70 (0.05) 0.81 (0.06) [12,37,39,64,66]
Phytosterol margarine $258 ($38) Total cholesterol 7.5% (1.9%) [42,43,74,75]
Dietary advice Yr 1: $132 ($213)
Yr 2+: $86 ($39)
Systolic BP Total cholesterol 1.6% (0.4%) 3.1%
(1.2%)
[47,76]
Lifestyle program Yr 1: $257 ($152)
Yr 2+: $172 ($58)
Systolic BP Total cholesterol 2.6% (0.5%) 3.3%
(0.6%)
[47,48,77]
Community heart health program Yr 1: $2.37 ($0.47) Yr 2+:
$1.60 ($0.32)
Systolic BP Total cholesterol 2.5% (0.7%)20.51% (0.6%) [9,44]
Mandatory salt reduction $0.81 ($0.08) mgNa/day men mgNa/day women 10.6 (0.74) 7.3 (0.53) [45,46,49,78]
Voluntary salt reduction (current practice) $0.49 ($0.05) mgNa/day men mgNa/day women 0.50 (0.03) 0.34 (0.02) [45,49]
Lipid-lowering (current practice) $683 RR IHD RR stroke 0.70 (0.05) 0.81 (0.06) [12,37]
BP-lowering (current practice) $170 RR IHD RR stroke 0.85 (0.04) 0.70 (0.05) [13,37,40]
NB. Values are mean and standard error, unless otherwise stated. BP – blood pressure; GP – general practitioner; NZ – New Zealand; RR – relative risk; IHD – ischaemic
heart disease.
*All costs are adjusted to 2008 Australian dollars using consumer price indices [79], health sector inflators [64] and purchasing power parities [19] where relevant.
**Table A2 provides further detail of sources and assumptions underlying the measurement of intervention costs and effects.
doi:10.1371/journal.pone.0041842.t001
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the predicted risk to fit the actual observed risk in the Australian
population, by age and sex. The predicted risk is then used to
determine: (a) the numbers of Australians who are eligible for each
intervention (or intervention combination); and (b) their initial
cardiovascular disease risk, relative to the mean risk in the
population, by age and sex.
Of those patients eligible to receive intervention, we assume that
40% will no longer be adherent after 12 months, based on rates of
discontinuation with blood pressure-lowering and cholesterol-
lowering therapies in Australia [35,36].
Intervention Costs and Effects
The modelled measures of intervention costs and effects are
summarised in Table 1 with further detail available in Table A2 of
the supplementary text.
Drug costs are based on prices in Australia’s Pharmaceutical
Benefits Scheme (PBS) list of tax-subsidised drugs [37]. Each cost is
estimated as an average across the class, weighted by the mix of
scripts provided in 2008 for an equivalent standard dose [38,39]
(e.g. 40 mg/day simvastatin, 20 mg/day atorvastatin, 10 mg/day
rosuvastatin and 80 mg/day pravastatin) [18,38]. The costs of
lipid-lowering and blood pressure-lowering drugs used in current
practice are derived from recorded PBS cost data from the
baseline year of 2008, using general practice data [40] to estimate
the mix of blood pressure-lowering drugs in preventive practice.
Each intervention also includes the costs of initial and follow-up
GP visits and blood tests for measurement of lipid levels and on-
going monitoring (e.g. monitoring of renal function for patients on
ACE inhibitors), based on the listed prices in Australia’s Medicare
Benefits Schedule (MBS) [41].
The cost of phytosterol-enriched margarine is derived from a
price survey of all available products available at the two major
Australian supermarket chains, assuming that each product
contains the Australian standard concentration of plant sterols
(82 g per kg of margarine [42]) and that 3.4 g of plant sterols are
required each day to achieve a beneficial effect [43].
The cost of the community heart health program is based on the
bottom-up costing of the Hartslag Limburg cardiovascular
prevention project [44].
The cost of the current voluntary program for salt reduction in
breads, margarines and cereals is derived from the proportion of
products participating in the current Heart Foundation program
[45] and the annual fee per product (C. Colyer, Heart Foundation;
personal communication, 18 June 2009). Costs of legislative
changes and enforcement for the mandatory program are derived
from World Health Organisation unit costs (www.who.int/choice/
costs/en/) in Australia and resource use [46].
The costs of dietary advice from a GP or dietitian and costs of
participation in a lifestyle program are based on Australian
Government costs for GP [41], dietitian [47] and/or exercise
physiologist [48] attendance and estimates of the number of initial
and follow-up visits.
Measures of intervention efficacy are based on meta-analyses of
relevant randomised controlled trials, with the exception of
voluntary and mandatory salt reduction, where program effec-
tiveness is determined from a New Zealand study of the sodium
reduction program [45] and current Australian data on consump-
tion of breads, margarines and cereals [49] (Table 1 A2). For
interventions that measure outcomes as a change in blood pressure
or cholesterol (e.g. dietary advice, phytosterol margarine), reduc-
tions in relative risks of ischaemic heart disease and stroke are
derived from the proportional changes found in meta-analyses of
blood pressure-lowering and statin drug trials. A 1% reduction in
systolic blood pressure is associated with 3.4% reduction in relative
risk of ischaemic heart disease and 6.3% reduction in relative risk
of stroke; and a 1% reduction in total cholesterol is associated with
1.8% reduction in relative risk of ischaemic heart disease and
0.80% reduction in relative risk of stroke [13,50,51]. For the salt
interventions, a change in blood pressure is first derived, by age
and sex, using the relationships between sodium and systolic blood
pressure derived by Law et al. [52]. The efficacy of interventions
involving combinations of interventions (e.g. a statin and a
diuretic) are determined multiplicatively [53] (e.g. using the
intervention effect data in Table 1, the relative risk of ischaemic
heart disease with a combination of statin and diuretic is
0.7060.86 = 0.602). For the interventions that have an effect on
salt, blood pressure or cholesterol, the reductions in relative risks of
disease are first derived, before being combined with other
interventions multiplicatively.
Cost-effectiveness Modelling
Cost-effectiveness analysis is carried out using the ‘generalised
cost-effectiveness analysis’ approach developed for the World
Health Organisation [54], in which all interventions (including
current practice) are evaluated against a theoretical ‘do nothing’
(i.e. do none of the interventions of interest in the analysis)
comparator. This approach allows explicit estimation of the cost-
effectiveness of current practice, it avoids artificially making an
intervention look more favourable if compared against inefficient
current practice, and it allows the optimal mix of interventions to
be evaluated. We back-calculate disease rates under the ‘do
nothing’ scenario using the same parameters of intervention
effectiveness, adherence and costs that are used in the cost-
effectiveness analyses. Hence, when current practice is modelled
from the ‘do nothing’ scenario, the model reproduces the levels of
disease currently observed. Current use of CVD preventive
therapies is derived from AusDiab [34] and general practice data
[40,55].
We use a discrete time Markov model to simulate costs and
health outcomes for the population that is eligible for each
intervention (or intervention combination), in five-year age and
sex cohorts. The Markov model has four primary health states,
with transition rates capturing probabilities of incidence and case
fatality for fatal and non-fatal IHD and stroke events. Probabil-
ities of gastrointestinal (GI) bleeds and hemorrhagic stroke are
taken into account as side-effects of aspirin therapy. Rates are
derived from Australian hospital and mortality databases [30,31],
the Perth MONICA study [32] and the NEMESIS [33] study.
Trends are incorporated to capture underlying changes in IHD
and stroke incidence and case fatality over time [56]. Further
details of the modelling methods and inputs are provided in Text
S1 and Text S2.
The total years of life lived by the population, both with and
without intervention, are adjusted for time spent in ill health using
utility or disability weights that capture the average quality of life
or ‘disability’ experienced at each age and sex, with or without
ischaemic heart disease, stroke or a GI bleed. This weighting
process can be carried out using utility weights to derive quality-
adjusted life years (QALYs), or using disability weights to derive
the loss of health-related quality of life captured in disability-
adjusted life years (DALYs). Although similar survey techniques
are used to elicit health state preferences for both utility and
disability weights, health state preferences for the QALY weights
are typically elicited from surveys of patients or the general
population while health state preferences for the DALY weights
have been elicited from expert panels. A comparison of the utility
and disability weights for ischaemic heart disease, stroke, GI bleeds
and all other ‘background’ disability can be found in Text S1. In
Cardiovascular Prevention Cost-Effectiveness
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41842
these analyses, we base our results on health gain measured in
DALYs, but since there is debate about when QALYs or DALYs
are the superior measure [57], we also evaluate cost-effectiveness
in QALYs to determine the impact (if any) of the QALY or DALY
choice on cost-effectiveness results.
Using Markov model predictions of the years of life lived and
time spent in ill health, we simulate costs of treating IHD, stroke
and GI bleed events. Annual costs in the initial year of illness and
in subsequent years are determined from hospital in-patient costs
[58], out-of-hospital expenses [59] and NEMESIS data for stroke
[60]. All costs are adjusted to Australian dollars in the year 2008
using health system deflators [61].
We simulate costs and health outcomes over time until everyone
in the population has died. All future costs and health outcomes
are discounted at a rate of 3% [62]. Cost-effectiveness ratios are
then evaluated in Australian dollars per DALY (or QALY) for the
year 2008. In multivariate probabilistic uncertainty analysis, using
Monte Carlo simulation, we derive 95% uncertainty intervals for
all outcome measures and determine the probability of each
intervention being cost-effectiveness against a cost-effectiveness
threshold of $50,000/DALY [63].
Results
Mandating more moderate use of salt in breads, margarines and
cereals is easily the most effective (Table 2) and cost-effective
(Table 3) strategy for primary prevention of CVD; it produces the
biggest improvements in population health, and can save money
for the health sector. The blood pressure-lowering drugs, including
diuretics, calcium channel blockers and ACE inhibitors, are also
cost-effective. If provided to people with at least 5% risk of a
cardiovascular event in the next five years, these drugs can
improve health for less than $50,000 per DALY.
Blood pressure-lowering with beta-blockers, although cost-
effective, has a lower probability of improving population health
than diuretic, calcium channel blocker and ACE inhibitor options,
and would not be recommended in preference to these three
readily available and cost-effective drugs. Aspirin, also cost-
Table 2. Effectiveness of the interventions for primary prevention of CVD, when evaluated individually against the partial null ‘do
nothing’ strategy and when evaluated as an addition to the most cost-effective package.
Intervention and target group
Health gain of intervention when
implemented individually (DALYs)*
Health gain of intervention when added to the
package (DALYs)*
Mandatory salt limits (all risk levels) 80,000 (60,000 to 100,000) 80,000 (60,000 to 100,000)
Diuretic ($15% risk) 39,000 (22,000 to 59,000) 38,000 (22,000 to 58,000)
Diuretic (10–14% risk) 40,000 (23,000 to 61,000) 39,000 (22,000 to 59,000)
Diuretic (5–9% risk) 77,000 (43,000 to 120,000) 75,000 (42,000 to 110,000)
Ca channel blocker ($15% risk) 37,000 (24,000 to 54,000) 28,000 (18,000 to 41,000)
Ca channel blocker (10–14% risk) 39,000 (25,000 to 55,000) 29,000 (18,000 to 42,000)
ACE inhibitor ($15% risk) 31,000 (18,000 to 47,000) 20,000 (12,000 to 30,000)
Ca channel blocker (5–9% risk) 74,000 (47,000 to 110,000) 56,000 (34,000 to 81,000)
ACE inhibitor (10–14% risk) 32,000 (19,000 to 49,000) 21,000 (13,000 to 31,000)
ACE inhibitor (5–9% risk) 62,000 (36,000 to 95,000) 40,000 (24,000 to 61,000)
Statin ($15% risk) 41,000 (24,000 to 62,000) 25,000 (15,000 to 38,000)
Comm. heart program (all risk levels) 3,000 (1,500 to 4,700) 2,600 (1,300 to 4,000)
Statin (10–14% risk) 43,000 (25,000 to 65,000) 27,000 (16,000 to 40,000)
Statin (5–9% risk) 85,000 (50,000 to 130,000) 51,000 (30,000 to 77,000)
Dietary advice ($15% risk) 180 (110 to 280) 82 (46 to 130)
Dietary advice (10–14% risk) 190 (110 to 290) 86 (48 to 140)
Dietary advice (5–9% risk) 370 (210 to 580) 160 (91 to 270)
Phytosterol ($15% risk) 160 (82 to 260) 80 (38 to 130)
Phytosterol (10–14% risk) 170 (86 to 270) 84 (40 to 140)
Phytosterol (5–9% risk) 330 (170 to 540) 160 (77 to 270)
Aspirin ($15% risk) 19,000 (7,200 to 33,000) Not included in optimal package**
Aspirin (10–14% risk) 20,000 (7,700 to 35,000) Not included in optimal package**
Aspirin (5–9% risk) 39,000 (16,000 to 68,000) Not included in optimal package**
Beta-blocker ($15% risk) 21,000 (5,200 to 39,000) Not included in optimal package**
Beta-blocker (10–14% risk) 22,000 (5,400 to 40,000) Not included in optimal package**
Beta-blocker (5–9% risk) 42,000 (10,000 to 79,000) Not included in optimal package**
Lifestyle program ($15% risk) 250 (160 to 360) Not included in optimal package**
Lifestyle program (10–14% risk) 270 (170 to 380) Not included in optimal package**
Lifestyle program (5–9% risk) 520 (330 to 740) Not included in optimal package**
*Values are mean and 95% uncertainty interval, rounded to two significant figures. DALY – Disability-adjusted life year.
**Intervention not included in the optimal package because a more cost-effective alternative is available.
doi:10.1371/journal.pone.0041842.t002
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effective on average, has a much higher probability of causing
harm than the other drugs evaluated; if other more cost-effective
drugs are first provided, the potential health benefits of aspirin are
reduced, and it is no longer a cost-effective strategy for primary
prevention of CVD.
No other interventions represent good value for money
(Figure 1). Statin drugs, including off-patent simvastatin, are
currently very expensive in Australia and a community heart
health program can achieve only small improvements in
population health. These interventions, although cost-effective if
implemented as isolated strategies, are not cost-effective if other
more cost-effective strategies (mandatory salt reduction and blood
pressure-lowering drugs) are first provided. The behaviour change
interventions, including dietary advice, participation in a lifestyle
program and switching to phytosterol-enriched margarine, can
achieve only small improvements in population health and are
least cost-effective of all the primary prevention strategies. Adding
any of these interventions to the prevention package is very bad
value for money at more than $1 million per DALY.
The current practice combination of blood pressure-lowering
drugs, statin drugs, dietary advice and voluntary participation of
food manufacturers in limiting salt use in processed foods, is
inefficient compared to the optimal approach of mandating more
moderate use of salt and providing diuretics, calcium channel
blockers and ACE inhibitors for everyone with at least 5%
cardiovascular risk (Figure 2). Providing the optimal package of
interventions could reduce current health care expenditure of the
Australian Government by $3.7 billion, while achieving more than
double the improvements in population health, over the lifetime of
the population (Table 4).
Reducing the costs of statin drugs would produce even greater
benefits (Figure 3). With a reduction to the current price in New
Zealand, statins would be a very cost-effective addition to the
optimal package (more cost-effective than the blood pressure-
lowering options). With the addition of cheaper statin drugs, the
optimal intervention package could reduce current health care
expenditure by $4.2 billion and achieve triple the population
health that is achieved with current intervention choices (Table 4).
Table 3. Cost-effectiveness of the interventions for primary prevention of CVD, when evaluated individually against the partial null
‘do nothing’ strategy and when evaluated as an addition to the most cost-effective package.
Intervention and target group
Cost-effectiveness of intervention when
implemented individually ($/DALY)*
Cost-effectiveness of intervention when added to
the package ($/DALY)*
Mandatory salt limits (all risk levels) Dominant (Dominant to Dominant) Dominant (Dominant to Dominant)
Diuretic ($15% risk) Dominant (Dominant to $5,600) Dominant (Dominant to $5,600)
Diuretic (10–14% risk) $2,000 (Dominant to $10,000) $2,000 (Dominant to $10,000)
Diuretic (5–9% risk) $5,800 (Dominant to $16,000) $5,800 (Dominant to $16,000)
Ca channel blocker ($15% risk) $7,900 ($3,300 to $14,000) $7,900 ($3,300 to $14,000)
Ca channel blocker (10–14% risk) $12,000 ($6,700 to $20,000) $12,000 ($6,700 to $20,000)
ACE inhibitor ($15% risk) $10,000 ($4,800 to $21,000) $10,000 ($4,800 to $21,000)
Ca channel blocker (5–9% risk) $19,000 ($12,000 to $29,000) $19,000 ($12,000 to $29,000)
ACE inhibitor (10–14% risk) $15,000 ($8,400 to $28,000) $15,000 ($8,400 to $28,000)
ACE inhibitor (5–9% risk) $23,000 ($14,000 to $40,000) $23,000 ($14,000 to $40,000)
Statin ($15% risk) $28,000 ($18,000 to $46,000) $28,000 ($18,000 to $46,000)
Comm. heart program (all risk levels) $44,000 ($19,000 to $100,000) $44,000 ($19,000 to $100,000)
Statin (10–14% risk) $36,000 ($25,000 to $59,000) $36,000 ($25,000 to $59,000)
Statin (5–9% risk) $51,000 ($37,000 to $81,000) $51,000 ($37,000 to $81,000)
Dietary advice ($15% risk) $1,000,000 ($610,000 to $2,400,000) $1,000,000 ($610,000 to $2,400,000)
Dietary advice (10–14% risk) $1,100,000 ($730,000 to $3,000,000) $1,100,000 ($730,000 to $3,000,000)
Dietary advice (5–9% risk) $1,400,000 ($920,000 to $3,900,000) $1,400,000 ($920,000 to $3,900,000)
Phytosterol ($15% risk) $3,200,000 ($1,900,000 to $5,900,000) $3,200,000 ($1,900,000 to $5,900,000)
Phytosterol (10–14% risk) $3,900,000 ($2,400,000 to $7,300,000) $3,900,000 ($2,400,000 to $7,300,000)
Phytosterol (5–9% risk) $4,900,000 ($3,000,000 to $9,300,000) $4,900,000 ($3,000,000 to $9,300,000)
Aspirin ($15% risk) $1,800 (Dominant to $18,000) Not included in optimal package**
Aspirin (10–14% risk) $3,500 (Dominant to $24,000) Not included in optimal package**
Aspirin (5–9% risk) $8,300 (Dominant to $34,000) Not included in optimal package**
Beta-blocker ($15% risk) $10,000 ($1,100 to $74,000) Not included in optimal package**
Beta-blocker (10–14% risk) $15,000 ($3,300 to $94,000) Not included in optimal package**
Beta-blocker (5–9% risk) $22,000 ($7,700 to $130,000) Not included in optimal package**
Lifestyle program ($15% risk) $1,400,000 ($960,000 to $2,500,000) Not included in optimal package**
Lifestyle program (10–14% risk) $1,600,000 ($1,100,000 to $3,200,000) Not included in optimal package**
Lifestyle program (5–9% risk) $2,100,000 ($1,400,000 to $4,100,000) Not included in optimal package**
*Cost-effectiveness ratios are median and 95% uncertainty interval, rounded to two significant figures. Where the ratio is Dominant, the intervention is cost-saving.
**Intervention not included in the optimal package because a more cost-effective alternative is available.
doi:10.1371/journal.pone.0041842.t003
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A number of factors influence the total costs and health gain of
the optimal package of interventions, including discount rate,
addition of other health care costs in added years of life, CVD
trends and measurement of health in QALYs rather than DALYs,
but these factors do not influence the order of interventions in the
pathway (Figure 3 and Text S3). The optimal intervention
package of mandatory limits on salt, diuretics, calcium channel
blockers and ACE inhibitors, which is determined by reference to
the $50,000/DALY threshold, is unchanged under all scenarios.
However, two interventions, the community heart health program
and the addition of statin drugs for everyone at 10 to 15% CVD
risk, only just exceed the $50,000 per DALY threshold, and under
assumptions that improve intervention cost-effectiveness, including
lowering discount rates and ignoring current downward CVD
trends, these two interventions would be included in the optimal
intervention package The individually-targeted behaviour change
interventions, though, are not cost-effectiveness under any
scenario evaluated.
Discussion
To achieve best value for money in the primary prevention of
CVD, the Australian government must take a tougher approach in
mandating limits on salt in processed foods (bread, margarine and
cereal), and fund a combination of diuretic, calcium channel
blocker, ACE inhibitor and (low cost) statin drugs for everyone
found to have at least a 5% five-year risk of CVD when visiting
their local GP. If implemented in Australia, this package of
interventions could achieve a three-fold improvement in current
population health and reduce current lifetime health care
expenditure by $4.2 billion (Australia’s total health care expendi-
ture is around $100 billion annually [64]). Current recommenda-
tions for lifestyle behaviour-change interventions as a first-line
strategy for CVD prevention should be reconsidered; these
interventions are poor value for money, achieving only trivial
gains in population health at a very high cost.
Our findings are robust to modelling assumptions around
discount rate, inclusion of other non-CVD health care costs in
added years of life, and choice of health metric (DALY versus
QALY), but are sensitive to drug price. It is likely, therefore, that
the Australian cost-effectiveness results will broadly reflect cost-
effectiveness of primary prevention strategies in other countries
with similar epidemiological and health system characteristics (e.g.
United Kingdom and New Zealand), with the exception of the
results on statin drugs. Australia currently pays around five times
the average price paid for statin drugs in other OECD countries
[14], and at this price they are not a cost-effective addition to the
intervention package. Australian legislative changes in November
2010 [65] will ensure a 16% cut in the price of the two most
expensive statins (atorvastatin and rosuvastatin) when they come
off patent in 2012, but much larger price cuts will be needed if
Australia (2008A$1.47 per 40 mg simvastatin [37]) is to match
prices paid in New Zealand (2008A$0.06 per 40 mg simvastatin
[66]) or the United Kingdom (2008A$0.11 per 40 mg simvastatin
[67]).
Our results are broadly consistent with the results of previous
analyses from WHO-CHOICE [11], Argentina [22] and Vietnam
Figure 1. The cost-effectiveness acceptability frontier, shown for values of the cost-effectiveness threshold up to $150,000/DALY.
Addition of the interventions that are not visible on the graph, is not optimal until much higher cost-effectiveness thresholds (dietary advice above
$2.4 million/DALY and phytosterol margarine above $6.7 million/DALY).
doi:10.1371/journal.pone.0041842.g001
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[21]. Our exclusion of aspirin from the optimal intervention
package recommended in WHO-CHOICE, and replacement of a
beta-blocker with a combination of ACE-inhibitor and calcium
channel blocker, better reflect cost-effectiveness based on current
drug choices and up-to-date evidence of drug efficacy. The cost-
effective (even cost-savings) of a population-wide approach to salt
reduction in this modelling study is consistent with the results of all
three previous studies that evaluated the relative cost-effectiveness
Figure 2. The cost-effectiveness of current practice and the optimal intervention pathway (NB. CCB – calcium channel blocker;
ACEi – ACE inhibitor; CHHP – community heart health program). Interventions are added to the mix in order of cost-effectiveness, thus
the pathway reflects the efficiency frontier. The pathway is shown as a solid line where the incremental cost-effectiveness of adding an
intervention to the mix is under the cost-effectiveness threshold of $50,000/DALY, and shown as a dashed line where the addition of the next
intervention is not cost-effectiveness (i.e. it exceeds the threshold of $50,000/DALY).
doi:10.1371/journal.pone.0041842.g002
Table 4. Lifetime costs and health gain of the current practice for CVD prevention and of the most cost-effective package of
interventions under different discounting and costing assumptions.
Current practice Cost-effective package*
Cost-effective package* + lower cost
statins**
Lifetime health gain (Thousands
DALYs)
190 (140 to 240) 430 (310 to 570) 530 (370 to 710)
Intervention cost to government
(2008A$billion)
$7.1 ($5.7 to $8.5) $5.5 ($3.9 to $7.3) $6.3 ($4.5 to $8.4)
Intervention cost to patients
(2008A$billion)
$1.6 ($1.3 to $1.9) $2.0 ($1.4 to $2.7) $2.1 ($1.5 to $2.9)
Disease treatment costs averted
(2008A$billion)
2$2.2 (2$3.0 to 2$1.5) 2$4.8 (2$6.9 to 2$3.0) 2$6.1 (2$9.0 to 2$3.8)
Net lifetime cost (2008A$billion) $6.5 ($5.1 to $8.0) $2.8 ($1.1 to $4.6) $2.3 ($0.51 to $4.3)
*Cost-effective package includes population-wide mandatory limits on salt in breads, margarines and cereals, and a mix of diuretic, calcium channel blocker and ACE
inhibitor drugs for everyone with at least 5% risk of a CVD event in the next five years.
**Statins provided for everyone with at least 5% risk of a CVD event in the next five years, at an annual cost of $18.25 (equivalent to the current price in New Zealand).
doi:10.1371/journal.pone.0041842.t004
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of interventions for primary prevention of CVD. Policy-makers
and food manufacturers would do well to heed this growing body
of evidence showing the large population health gains to be made
by moderating salt use in processed foods.
While cost-effectiveness ratios for the individually-targeted
lifestyle interventions were very unfavourable, our analyses do
not capture any additional benefits from reduced smoking,
increased physical activity, or other possible lifestyle changes,
unlike with the analyses of drug interventions, where health
benefits are entirely mediated by changes in modelled blood
pressure or cholesterol. This means that we are likely underesti-
mating the health benefits of the lifestyle interventions. We do find,
however, that even if we add in the DALYs and treatment costs
averted by lifestyle intervention changes in physical activity, fruit
and vegetable intake, weight loss, alcohol intake and smoking,
which have all been modelled separately in other comparable
Australian analyses [68], the cost-effectiveness ratio for the lifestyle
program is still unfavourable (,$76,000/DALY) despite likely
double-counting of cardiovascular disease benefits. A more
accurate analysis of the combined DALY effect, taking interactions
in lifestyle risks and correlations in risk behaviours in individuals
into account, is however recommended.
The policy-makers behind England’s Vascular Check program
should be concerned about the potentially poor value for money of
the lifestyle behaviour-change interventions in Australia. The
Vascular Check program was predicted to be highly cost-effective
by England’s Department of Health [20], but their estimate of
health gain was based on summing selected QALY values
gathered from a range of other intervention studies, rather than
modelling epidemiological outcomes of the intervention combina-
tions in the population over time, taking target population
characteristics (e.g. age and sex-specific mortality, blood pressure
and cholesterol distributions), long-term disease trends and
combined intervention effects into account. Assistance with
changing lifestyle needs to be an option, particularly for those
wanting to avoid medication in the first instance, but England’s
Department of Health would be wise to thoroughly evaluate cost-
effectiveness of the current pilot programs before rolling the
program out on a national scale, to guard against the possibility of
major cost blow-outs with only negligible improvements in
population health.
It is also important to evaluate the longer term outcomes of the
lifestyle and other cardiovascular disease interventions. Trials of
lifestyle interventions in particular are often short-term (e.g. less
than two years follow-up). We have assumed that the effects (and
costs) of these interventions will be sustained for those who
continue to participate, but further evidence is needed to clarify
the sustainability of different intervention approaches.
In Australia, it is vital that policy-makers recognise just how far
away the country is from optimal prevention of CVD. The remedy
Figure 3. Sensitivity of the optimal pathway to increased and decreased discounting (5% and 0%), to the addition of other non-
cardiovascular health care costs in added years of life, the measurement of health gain in QALYs rather than DALYs, and to a
reduction in the cost of statin drugs to the much lower price in New Zealand (NB. the order of interventions is altered only by the
reduction in statin price, with statins becoming a more cost-effective intervention option than the blood pressure-lowering drugs).
doi:10.1371/journal.pone.0041842.g003
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is three-fold. The first step is to stand firm against industry pressure
and redress current policies around statin dug pricing; this alone
would produce immediate Government savings of $500 million in
the first year. The second step is to address current inefficiencies in
primary care. Australian GPs have been slow to adopt tools for
absolute risk assessment [69] with prescribing still largely guided
by a confusing mix of rules and criteria defining thresholds for
treatment of high blood pressure and cholesterol. The various
guidelines are currently being unified, which will remove some of
the confusion, but it is vital that GPs are given sufficient
information, incentives and support to ensure that absolute risk-
based screening and prescription of the most cost-effective drug
options become standard practice. Web-based tools that integrate
cardiovascular absolute risk assessment with electronic medical
record systems may also be of benefit [70]. Thirdly, and most
importantly, the Australian Government must enforce moderate
salt limits in some processed foods. Limits are currently voluntary
for food manufacturers. While the industry may initially resist
change, the enforcement of limits will lead to large and immediate
improvements in population health.
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